Investigation of novel HCV therapies: Boscia angustifalia & Boscia senegalensis extracts loaded on galactosylated chitosan nanoparticles synthesized by eco-friendly method for HCV treatment

Bibliographic Information
Authors: Rashdan H.R.M.; Okasha H.; Salem M.M.; Abd El-Hady B.M.; Ekram B.
Journal: International Journal of Biological Macromolecules
Publisher: Elsevier B.V.
Publication Date: August 2023
Volume / Issue: Volume 245
Article No.: 125420
ISSN: 1418130
DOI: 10.1016/j.ijbiomac.2023.125420
Scopus: View on Scopus
PubMed: 37353115
Document Type: Article
Authors and Affiliations
Rashdan H.R.M., Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt; Okasha H., Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt; Salem M.M., Photochemistry and Plant Systematic Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt; Abd El-Hady B.M., Polymers and Pigments Department, Chemical Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt; Ekram B., Polymers and Pigments Department, Chemical Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt
Abstract
Hepatitis C virus (HCV) is a major causative agent of chronic liver diseases including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Treatment of HCV has evolved from early interferon monotherapy to the current all-oral regimens using direct-acting antivirals. However, antiviral resistance has become a critical issue in the treatment of chronic hepatitis C after receiving therapy with direct-acting antivirals (DAA) with a 0.5 % chance of the hepatitis C virus recurrence, similar to other chronic viral infections. So, retreatment options following treatment failure have become crucial issues. Hence, this study aims to investigate a new promising therapy for HCV. In the field of nanomedicine, chitosan nanoparticles are well-known delivery systems that are frequently used as polymeric carriers. Galactosylated chitosan nanoparticles have been widely applied in HCV treatment. In this study, we have modified galactosylation by an eco-friendly method using L-ascorbic instead of hazardous reagents and we have loaded it with newly tested two Boscia extracts each in three different concentrations. The synthesized chitosan nanoparticles showed two dispersion peaks, at 196 ± 29 nm and 1.33 ± 0.36 μm, with a zeta potential of +3.3 ± 0.4 mV with high stability in a range of 40.7 mV. The percentage of encapsulation of Boscia angustifalia extract was found to be 46.58 ± 1.33 % and for Boscia senegalensis extract was 9.77 ± 0.33 %. The release of Boscia angustifalia extract from the nanoparticles was about 40 % in acidic media after 180 min and about 60 % in normal pH. However, the release of Boscia senegalensis extract was 20 % in acidic media and 56 % in normal media after 24 h. Testing of these two newly developed composites against HCV was carried out using an in vitro system for the production of hepatitis C virus (HCV) which was established by infection of human hepatoma cells. Evidence for persistent virus production was monitored by the ELISA technique using an anti-HCV-specific antibody. Results obtained showed that all samples had an anti-HCV activity that increased by increasing concentration, and Boscia angustifalia had remarkable anti-HCV activity compared to Boscia senegalensis. © 2023 Elsevier B.V.
Keywords
Boscia angustifalia & Boscia senegalensis extracts; Drug delivery; Galactosylated nano chitosan; HCV; Antiviral Agents; Carcinoma, Hepatocellular; Chitosan; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Nanoparticles; Controlled drug delivery; Environmental protection; Interferons; Medical nanotechnology; Synthesis (chemical); Targeted drug delivery; Viruses; antivirus agent; Boscia angustifalia extract; Boscia senegalensis extract; chitosan nanoparticle; plant extract; unclassified drug; nanoparticle; Acidic media; Antivirals; Boscium angustifalia & boscium senegalensis extract; Chitosan nanoparticles; Chronic hepatitis; Eco-friendly; Galactosylated chitosan; Hepatitis C virus; Synthesised; antiviral therapy; Article; Boscia angustifalia; Boscia senegalensis; concentration (parameter); controlled study; cytotoxicity; dispersion; drug release; encapsulation; enzyme linked immunosorbent assay; Fourier transform infrared spectroscopy; Hep-G2 cell line; human; human cell; in vitro study; medicinal plant; nanomedicine; nonhuman; particle size; pH; scanning electron microscopy; transmission electron microscopy; zeta potential; chronic hepatitis C; liver cell carcinoma
Citation Information
Scopus Citations: 7
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
